BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Interest Expense Over TimeContracting
Percentile Rank79
3Y CAGR-7.3%
5Y CAGR+40.3%
Studio
Year-over-Year Change

Interest expense on outstanding debt

3Y CAGR
-7.3%/yr
vs +81.3%/yr prior
5Y CAGR
+40.3%/yr
Recent deceleration
Acceleration
-88.6pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
5.4x
Strong expansion
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$78.87M-19.9%
2024$98.52M-9.0%
2023$108.24M+9.2%
2022$99.09M+67.1%
2021$59.29M+308.9%
2020$14.50M+21.9%
2019$11.89M+29.6%
2018$9.18M+7.1%
2017$8.56M+32.0%
2016$6.49M-